Thursday, May 12, 2011 1:35:06 PM
The Bank Of America call is a worth a listen IMO. JJ presented and while nothing earth shattering was revealed a couple of nice to know things were a couple I recall:
1-Pompe basically done dosing the 1st dose weight 4-6 weeks and go on to second cohort. No AE's. Think end of the year would be at third (20mg) cohort.
2-It seems the company is already exploring the possibility of a 3rd manufacturing plant. It would be outside the US for tax reasons and from what JJ was saying they may have even priced a couple as he said they are selling a discounts to what it would cost to build. Think around 2016 (2nd year of GALNS if everything goes well) would need one.
1-Pompe basically done dosing the 1st dose weight 4-6 weeks and go on to second cohort. No AE's. Think end of the year would be at third (20mg) cohort.
2-It seems the company is already exploring the possibility of a 3rd manufacturing plant. It would be outside the US for tax reasons and from what JJ was saying they may have even priced a couple as he said they are selling a discounts to what it would cost to build. Think around 2016 (2nd year of GALNS if everything goes well) would need one.
Recent BMRN News
- BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency • PR Newswire (US) • 05/18/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/11/2026 09:01:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 05:17:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 05:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:07:23 PM
- BioMarin Reports First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 05/04/2026 08:05:00 PM
- BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting • PR Newswire (US) • 05/02/2026 07:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 12:45:12 PM
- BioMarin Completes Acquisition of Amicus Therapeutics • PR Newswire (US) • 04/27/2026 12:44:00 PM
- BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET • PR Newswire (US) • 04/27/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:20:56 PM
- BioMarin Announces Board Leadership Transition • PR Newswire (US) • 04/21/2026 08:23:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 08:21:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:19:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:53:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:50:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:48:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:34:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 05:42:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:48:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 12:43:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 11:55:45 PM
